Use of Mullerian inhibiting substance for treating excess androgen states
AssigneeThe General Hospital Corporation
InventorsPatricia K. Donahoe, Jose Teixeira, Eric Fynn-Thompson
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating a condition or disease characterized by an excess of one or more androgens, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The present invention also provides a method of decreasing the level of one or more androgens to a level below the normal level, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The methods of the present invention are particularly well-suited for the treatment of prostatic cancer, polycystic ovarian disease, benign prostatic hypertrophy, and precocious puberty.
Claims15
A method of treating a condition or disease characterized by an excess of one or more androgens relative to a normal level, said method comprising administering an effective amount of MIS to a patient.
A method of decreasing the plasma level of one or more androgens, said method comprising administering to a patient an effective amount of MIS, wherein said amount of MIS is sufficient to decrease the plasma level of said one or more androgens below the normal level for said one or more androgens.
Dependencies are inferred from the claim text.